BBB seminar: Colin Clyne
Targeting orphan nuclear receptors in breast cancer
Hovedinnhold
Colin Clyne
Cancer Drug Discovery Laboratory, Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia
Most breast cancer patients have oestrogen-dependant disease that can be treated by blocking oestrogen action or synthesis. However, for those women with oestrogen-independent disease (or those whose tumours have developed resistance to endocrine therapies), few treatments are available. Recent expression profiling has revealed several nuclear receptors – proteins related to the oestrogen receptor – to be differentially expressed in various breast cancer subtypes, and to modulate breast cancer cell function. This presents opportunities for the development of novel therapeutics, particularly for patients with oestrogen-independent disease.
Chairperson: Marit Bakke, Department of Biomedicine
